Onesource Specialty Pharma Peer Comparison
NSE: ONESOURCE | BSE: 544292
₹1,532.20
₹14.70
(0.97%)
As on 28-Aug-2026IST
Market cap
₹17,579 Cr
Revenue (TTM)
₹1,543 Cr
P/E Ratio
--
P/B Ratio
3
Div. Yield
0 %
Edit
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
17,579 | 32,104 | 29,892 | 29,103 | 26,871 |
Revenue (₹ Cr) |
1,543 | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
-48.62 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
-3.12 | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-0.61 | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
-- | 78.49 | 103.71 | -- | 69.57 |
Price-To-Book |
3.00 | 6.38 | 22.27 | 3.64 | 15.55 |
Income Statement (₹ Cr)
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,543.34 | 3,564.00 | 1,935.80 | 9,205.28 | 1,461.80 |
|
Total Income
|
1,556.90 | 3,686.00 | 1,948.58 | 9,449.59 | 1,489.25 |
|
Total Expenditure
|
1,204.26 | 2,792.00 | 1,485.56 | 8,195.15 | 919.25 |
|
EBITDA
|
339.09 | 772.00 | 450.24 | 1,010.13 | 542.56 |
|
Depreciation
|
283.04 | 226.00 | 50.83 | 857.51 | 37.68 |
|
EBIT
|
56.05 | 546.00 | 399.41 | 152.62 | 504.88 |
|
Interest
|
125.52 | 217.00 | 40.84 | 342.73 | 3.77 |
|
Other Income
|
13.56 | 122.00 | 12.78 | 244.31 | 27.45 |
|
Exceptional Items
|
-11.36 | 12.00 | 0.00 | -216.88 | 0.00 |
|
Profit before Tax
|
-67.27 | 463.00 | 371.35 | -162.68 | 528.56 |
|
Provision for Tax
|
-18.65 | 49.00 | 83.14 | 209.13 | 141.21 |
|
Profit after Tax
|
-48.62 | 414.00 | 288.22 | -371.81 | 387.35 |
Liabilities (₹ Cr)
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
5,831.29 | 4,940.00 | 1,288.82 | 8,162.62 | 1,653.56 |
|
Minority Interest
|
0.00 | -5.00 | 0.00 | 0.00 | -1.13 |
|
Non-Current Liabilities
|
936.76 | 1,712.00 | 202.03 | 5,044.14 | 42.40 |
|
Current Liabilities
|
1,441.97 | 1,622.00 | 835.87 | 4,758.28 | 230.82 |
|
Total Liabilities
|
7,550.24 | 8,100.00 | 1,451.43 | 15,513.53 | 1,549.26 |
Assets (₹ Cr)
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
6,358.46 | 5,343.00 | 519.60 | 10,211.52 | 1,026.85 |
|
Current Assets
|
1,425.94 | 2,606.00 | 1,681.81 | 7,191.66 | 881.27 |
|
Total Assets
|
7,550.24 | 8,100.00 | 1,451.43 | 15,513.53 | 1,549.26 |
|
Total Debt*
|
771.59 | 1,859.00 | 393.17 | 4,720.27 | 8.18 |
|
Net Current Assets
|
-16.03 | 984.00 | 845.94 | 2,433.38 | 650.46 |
|
Contingent Liabilities
|
1,164.76 | 770.26 | 12.25 | 99.76 | 15.38 |
Cashflow (₹ Cr)
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-67.85 | -22.00 | 159.18 | 892.30 | 118.34 |
|
Cash Flow from Investing Activities
|
-201.08 | -783.00 | -64.81 | -477.46 | -223.94 |
|
Cash from Financing Activities
|
412.01 | 409.00 | -39.81 | -440.83 | 261.12 |
|
Net Cash Inflow / Outflow
|
143.07 | -396.00 | 54.56 | -25.99 | 155.52 |
Ratios
Profitability Ratios
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
2.61 | 4.07 | 26.97 | 6.61 | 20.14 |
|
ROE (%)
|
-0.61 | 8.38 | 29.77 | -3.85 | 25.18 |
|
ROA (%)
|
-0.62 | 4.94 | 24.77 | -2.21 | 21.93 |
|
EBIT Margin (%)
|
3.63 | 15.32 | 20.63 | 1.66 | 34.54 |
|
Net Margin (%)
|
-3.12 | 11.23 | 14.79 | -3.93 | 26.01 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.29 | 18.37 | 46.65 | 0.78 | 40.90 |
|
EBIT Growth (%)
|
-74.22 | 252.26 | 62.13 | -70.53 | 124.50 |
|
Net Profit Growth (%)
|
-307.89 | 377.85 | 89.49 | -1,383.43 | 104.15 |
|
EPS Growth (%)
|
-295.04 | 1,001.33 | 78.60 | -484.84 | 42.32 |
|
Book Value Growth (%)
|
1,413.25 | 29.77 | 42.49 | 2.28 | 94.96 |
Valuation Ratios
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-487.20 | 80.56 | 102.12 | -93.01 | 69.57 |
|
Price / Book Value
|
3.00 | 6.38 | 22.27 | 3.64 | 15.55 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
|
EV/EBITDA
|
53.21 | 43.48 | 66.20 | 32.91 | 49.08 |
|
Market Cap (₹ Cr)
|
20,002.98 | 23,064.69 | 0.00 | 29,731.27 | 19,988.69 |
Solvency Ratios
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.10 | 0.31 | 0.11 | 0.53 | 0.01 |
|
Short term debt to equity ratio
|
0.07 | 0.11 | 0.54 | 0.12 | 0.02 |
|
Current Ratio
|
0.99 | 1.61 | 2.01 | 1.51 | 3.82 |
|
Quick Ratio
|
0.68 | 1.06 | 1.14 | 0.87 | 2.82 |
|
Interest Coverage
|
0.46 | 3.13 | 10.09 | 0.53 | 141.16 |
Operating Efficiency Ratios
| Onesource Specialty Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
44.72 | 16.50 | 26.28 | 23.44 | 24.80 |
|
Asset Turnover
|
0.20 | 0.43 | 1.66 | 0.55 | 0.83 |
|
Receivable days
|
59.60 | 60.36 | 47.59 | 77.05 | 90.06 |
|
Inventory Days
|
21.38 | 64.42 | 62.58 | 77.13 | 61.02 |
|
Payable days
|
107.62 | 218.94 | 228.78 | 173.49 | 96.06 |
|
Cash Conversion Cycle
|
-26.64 | -94.15 | -118.62 | -19.30 | 55.02 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
